Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Acute Myeloid Leukemia

NCT00594555 is registered in ClinicalTrials.gov with University of Cincinnati as lead sponsor.

NCT NCT00594555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00594555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Acute Myeloid Leukemia
Lead sponsor
University of Cincinnati
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2007
Completion date
November 30, 2008
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic myeloid leukemia, blast crisis